Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
If we could get the FDA excited about HepCide we might get them, and others, excited about the cancer related benefits. If...
Happy Holidays to all NanoViricides supporters.
I believe the sentiments expressed are largely genuine. (At least the first two comments. NNVC is down so I expect the boots are being laced for action.), They are not motivated by basher-manipulator trading models. But where the bashers were countered by strong supporter rebuttals the message of the pro midstream horse switchers will be harder to resist and harder to counter. The rapid value increase and potential for continued growth of their new darling is real. Only clinical setbacks will stop the climb.
Where the rodent, Greek and stat-cruncher failed to drive NNVC down to the low .40s the siren song of quick profit and respite/recovery from a long voyage on a tumultuous sea will succeed. For those of us long and strong I predict a trial bathed in red for the early months of 2013.
Happy New Year. 2014 can't come soon enough.
I totally agree. There's little to benefit a lifestyle in a $10M light manufacturing plant. The build is another in a long, consistent, series of progressive steps.
$10,000 is expensive if it offers no return. $10M is cheap if it enables a revenue stream of $100M/yr. The wisdom of investment cost must be measured against the return generated over the depreciation period.
2013 will be a productive and prosperous year.
One does not discover new lands without consenting to lose sight of the shore for a very long time." -- Andre Gide
I can see it now..."members of the board, with all disrespect...er, I mean, with all due respect, when will the SP finally sink to .41?
Any other ideas?
Thanks for the posting. For those of you who've invested in Nanoviricides for the science potential and who scour all media for the least bit of new data this is a welcome post. There are one or two very specific points of data in the letter that strengthen the argument for negative toxicity results and encouraging indications that oral application may have practical application across the broader development pipeline.
Be patient, tolerate and when possible benefit by the "shorters" and enjoy the ride. The next 18-24 months will be exciting.
For those of you interested in broadening your knowledge I recommend David Quammen's latest, Spillover. An informative and extremely well written exploration of zoonotic viral transmission.
All steps and timing announced are consistent with OneMed Place,December 2011, projected activities and timelines.
And I suppose Basi is a co-conspirator. Be confident that there is a structured plan and reasonable timeline. Basi, a publicly traded company with global footprint and an established reputation, would not risk their good name by allowing NNVC to announce a Tox study agreement without established, reasonable timelines.
Note the toss off reference to simultaneous efficacy study continuing in parallel to Tox studies. More flu strain efficacy testing?
Look back at calendar 2012. A steady output of progressive reports. Subtle but important distinctions communicated at a healthy pace, the result of low cost experiment.
Science history in review appears as dramatic as a thunderstorm with flashes of brilliance and explosive reports. Science in real time, in the present, is plodding. Progress comes only after sweat and toil, trial and error, blind alleys and far more failure then success in balance. A nascent pipeline targeting a broad range of virus has been narrowed and honed for a final push against a single illness. The market size for a flu "cure" is substantial and the illness, common and understood by the public, will open doors and funding for still larger markets.
For stockholders invested 6-7 years...you must feel the acceleration.
Corporate communications? Dammed if you do dammed if you don't.
Nanoviricides is propelled by science (with vision and hope sprinkled to taste). PR costs money. I prefer my share of this investment dedicated to the science not to placating the market and those too impatient for long term, speculative investing. BioPharm is not for the faint of heart or those who might need returns to support current expenses.
FluCide is ready for Tox and Human trials in 2013. Production volumes sufficient for Tox are in progress. Tox studies will be completed in q1-2 of 2013. Human tolerance for PEG has been established and all indicators point to successful Toxicity test results.
Australian regulatory process, the consulting firm hired and the timing of flu season down under suit the trajectory for a q3 human trial. Flu mitigation trials are short-lived. Results will be in by close of 2013.
Construction Permits are meandering through the bureaucratic process in CT. Nanoviricides in-house production or contracted third party production will be impacted by the timing. The outcome will impact cost and post FCC approval market readiness. The realities of in-house production and going it alone will favor a big-Pharma partnership. This outcome too will occur in late 2013.
The announcement reflects the positive results of lung tissue analysis. Previous PR related to this strain was limited to survival period. Nanoviricides continues to methodically pursue results. At each step a PR. At each step, demonstrated superiority to the current standard of treatment. Step by step they accomplish fulfillment of FDA Pre-IND guidance.
I don't believe you assumption is accurate. There may be some overlap but the work contracted through Kard is largely independent of the efforts undertaken by universities. University work has been focused on virus other than influenza. Kard, in recent timeframe, has been focused on various influenza strains.
That's good company. Thanks.
Here's a topic for discussion.
I've searched for information related to drug studies, positive and negative results, conducted by Kard Scientific. I'm interested in validating the standing of Kard. I've not found anything untoward or uncovered negative reports. But with all due respect the combination of research-for -hire and SAB participation demands investors have additional info to substantiate Kard's objectivity.
Thoughts anyone?
The higher immune response was associated with a 3cc oral dose. Efficacy was slightly less then had been observed in IV tests. Higher oral dosage is being considered to match or exceed IV efficacy. The elevated immune response was "surprising" to the researchers from Nanoviricides. Regardless of cause, as investors we should be pleased with the findings and hope they are repeated in subsequent testing.
http://en.wikipedia.org/wiki/Peyer%27s_patches
Peyer's Patch explained.
Cox, and the NNVC team, are theorizing as to why the immune system appears to show a stronger response when Nanoviricides are introduced orally versus IV. The Peyer's Patches theory speculates that weakened or disassembled influence virus, post encounter with "cides" in the digestive tract, encounter Peter's Patches and stimulate the body's immune response. A Peyer's Patch encounter,or not, of the actual Nanoviricides has nothing to do with the response. Oral application, by involving the digestive tract's auto immune capacities to the overall immune system response, provides an unintended improvement to efficacy.
The pattern you report is accurate. Perhaps Stanley Glick will alter the trend.
Don't rush into "take over" talk. Be patient. Play out tox, phase I/II and then license lines to big pharm. Hold the company. License the technology. There's value in the IP. There's value in the patents.
Don't clear the land, break the sod, labor through the planting only to sell the farm before harvest.
polyethylene glycol (PEG) is FDA approved and has been taken orally for a number of medical purposes for years. On its own the risk that PEG will be a source of toxicity is extremely small.
This post along with DrF's earlier post are emblematic of the best iHub has to offer. Together they represent the elevated dialogue that fellow investors can learn from and use as starting point for additional research. The exchange is a model of decorum to be followed by those genuinely interested in judging the validity and risk of complicated technology based investments. Thank you both.
I've researched your claim. Nothing I can find substantiates your assertion that Dr. Menon has ended his association with NNVC. Do you stand by your claim? Can you back your statement with, and provide links to, documentation? Does the veracity of your claim rest soley upon your reputation for unbiased honesty?
SSUR? A difficult journey to be sure. Many fellow travelers share the NNVC path now. For those of us committed to a long term strategy with NNVC the wreckage of SSUR introduces many of the anxieties one feels viewing carnage in the rear view mirror. Still, one can't move forward if paralyzed by failures of the past. Some perspective provided by other seasoned travelers would be valuable.
Buy on the lows. I agree. I continue to strengthen my position. If you believe the science behind Nanoviricides is sound and that the positive reports to date indicate reasonable odds of a positive future out come then the $25billion sited below is in Nanoviricides' future.
http://www.militaryaerospace.com/blogs/aerospace-defense-blog/2012/09/u-s-government-takes-threat-of-bird-flu-pandemic-seriously-spends-25-billion-for-medical-counterm.html
It's all fun and games until someone gets their lungs poked out.
Agreed, in due time human testing will definitively prove (or not), efficacy. If skepticism holds the share price down till then...buy more shares.
There are some that are skeptical about the moon landing. Can't please everyone.
Nanomaterial is a term that covers a very large set of materials, natural, industrial, environmental and of late engineered and purpose designed. Within the set of engineered purpose-designed manomaterials the variety of materials, intended purposes, chemical characteristics and manufacturing practices is large. A search of manomaterials will return leads that could take a lifetime to chase down. Narrow the search to nanomaterial toxicity and you'll find sufficient material to secure a phd. Nanoviricides' application is sufficiently unique that the US Patent Office recognizes and respects it uniqueness.
Your post is either the product of laziness or unwillingness to engage in the least bit of research. Or a ham handed attempt to throw cold water on recent positive news from NNVC and begin a campaign of unfounded doubt aimed at driving down share price.
Nanoviricides is dosed in the trillions of particles. Nanoviricides overwhelm the virus in the bloodstream true, but the human immune system is still exposed and responds by generating antibodies. Reported as 1866±90 micro-g/ml-plasma of anti-influenza antibody, and 1258±59 when administered as IV injections in 9/4 PR.
Nanoviricides give the immune system time and favorable odds in the 3 days needed for the immune system to begin generating natural immune response. Nanoviricides does the lion's share of destroying the viral attack but viral interaction with the immune system still occurs.
Parse the PR. Review previous PR and published articles. (Yes I know, non-peer reviewed articles.) Although still to be subjected to the rigor of phase I/II/III testing explanations of the underlying mechanisms, estimations of efficacy and market share projections have been forecast.
Nanopatent, you have been here since post #1. Please, learn to fish.
No argument intended, read or re-read Sept.4 PR. Whether the virus is encountered in the wild or via inoculation is incidental. Those who dose with Nanoviricide will achieve high levels of anti-influenza antibodies against whichever strain they encounter. And of significant importance, those who dose preventively will be "shielded" for weeks and will themselves develop anti-viral antibodies within days of an exposure.
Extrapolate beyond influenza. Medical professionals, who have always accepted risk as they battle epidemic, may finally have prophylactic protection.
Keep in mind, vaccine usage in the US is low. Globally, usage varies largely depending upon community standard of living and healthcare model. In a pandemic massive vaccine programs will be marshaled too late.
I own stock in Inovio. I hope they are successful. The science is simply not the same as Nanoviricides. Nanoviricides if for the vast number of individuals, vast majority, who do not inoculate. Nanoviricides is bigger than influenza. Anti-viral cure is a fundamental game changer. Nanoviricides changes the relationship between human and virus like penicillin altered the equation between human and bacteria. Inovio is a potential improvement in the way we treat flu today. Nanoviricides, if proven effective, changes the world. Nanoviricides fundamentally changes the balance of power.
The latest PR contains more detail and definitive information resulting from lung biopsies. There is a tone change. NNVC is openly challenging the medically accepted treatment.
Stick to the plan in play. FluCide tox in EU and human test in AU. Complete efficacy tests against dozen or so distinct strains. Directed energies will result in best possible opportunities in 2012-13. Limited resources need to be focused on a precise and cost effective path. Single thread to approval,
The potential to target cancer specific proteins with payload enhanced nanoviricides is certainly real. In that regard the article does present an additional line of business. (In fact it represents a return to the earliest days of TheraCour, therapeutic courier, when cell-specific transport of pharmaceutical payload was the primary vision.)
But the final sentence in paragraph 4 is most reassuring for NNVC’s current efforts. Reporting a critical characteristic of zero toxicity in Mega-dosage experimentation is fantastic. One of the next big milestones NNVC must achieve is to replicate these results in Human tests.
I would be thrilled by recent activity, and there may very well be work underway, but the images on Bing could be no more recent then early spring 2012.
Architectural drawings, construction plans, SOW with subcontractors and the permit process take time. Work is certainly being done. Andrew Hahn has been on board since May. I'm confident he's making progress. I'm also confident he's precise, cautious, methodical and accustomed to crossing his t's and dotting his j's before breaking ground. After 30 years at Bristol-Myers-Squibb I suspect he takes the tortoise view not the Bunny's. Hammers swinging, maybe. Nano's brewery equipment installed and cooking up "bug juice"?...too optimistic.
Any investors on the ground in proximity to the cGMP plant? Get out there and capture some current images with/without activity. A source on site would be a hero to readers.
Thanks for a terrific and informative post. Information that should be maintained nearby for quick reference and consultation prior to pressing Submit Post.